Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
Translating Science into Clinical Practice: New and Evolving Anti-Inflammatory MS Therapies
Tell a Friend About This EventTell a Friend

Translating Science into Clinical Practice: New and Evolving Anti-Inflammatory MS Therapies


When: Saturday
From 8:00 AM until 4:15 PM
Where: The Biltmore Hotel
Tel: (305) 445-1926
1200 Anastasia Avenue
Coral Gables, Florida  33134
United States
Susan Ratti


Register for this program

Translating Science into Clinical Practice: New and Evolving Anti-Inflammatory MS Therapies

This educational activity has been supported by a grant from Biogen Idec and Sanofi-Aventis US Genzyme .
Target Audience:The intended audience for this activity is neurologists, neurology residents and fellows, MS researchers, physician assistants, and nursing professionals.
    Program Overview:

    The Consortium of Multiple Sclerosis Centers cordially invites you to join our distinguished neurologic panel in an accredited educational activity designed for physicians and nursing professionals who specialize or have an interest in multiple sclerosis (MS). Co-chaired by Dr. Kottil Rammohan and Dr. Michael Kaufman, our internationally known faculty will present cutting-edge information about the benefits and risks of new and emerging therapies in MS.

    Learning Objectives:
    • Demonstrate increased current understanding of the immunology of multiple sclerosis in order to facilitate evidence-based decisions in the choice of disease modifying agents.
    • Analyze adverse events, monitoring procedures, or possible drug interactions associated with current and emerging disease modifying therapies to improve patient assessment and monitoring by MS healthcare professionals.
    • Modify patient management strategies by incorporating information drawn from this conference along with a range of evidence including peer-reviewed publications, clinical trials, other live meetings, and expert opinion.
    8:00 – 8:15Welcome and Overview –– Michael Kaufman, MD/Kottil Rammohan, MD
    New and Emerging Therapeutics and their Scientific Basis
    8:15 – 9:00Anti CD-52 Alemtuzumab –– Edward Fox, MD, PhD
    9:00 – 9:45Ocrelizumab –– Kottil Rammohan, MD
    9:45 – 10:00Break
    10:00 – 10:45Anti CD-25 Daclizumab –– John Rose, MD
    10:45 – 11:30Tolerance Directed Immunotherapies Employing Biodegradable PLG Nanoparticles – The Future of MS Treatment? –– Stephen Miller, MD
    11:30 – 12 noonPanel of presenters with Q and A
    12:00 – 1:00Luncheon
    1:00 – 1:45 Dimethylfumarate & Fingolimod –– Michael Kaufman, MD
    1:45 – 2:30 Balancing Safety with Efficacy –– Joseph Berger, MD
    2:30 – 2:45 Break
    2:45 – 3:30 Teriflunomide –– Jerry S. Wolinsky, MD
    3:30 – 4:00 Afternoon faculty panel with Q and A
    4:00 – 4:15 Evaluations and Wrap up
    Accreditation and Credit Designation:


    The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    CMSC designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Professionals:
    This activity is co-provided by Nurse Practitioner Alternatives and the Consortium of Multiple Sclerosis Centers.

    Nurse Practitioner Alternatives is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    This activity is awarded 6.25 continuing nursing education credits.

    Laurie Scudder, DNP, NP served as the nurse planner for this activity.

    Disclosure Policy:
    Disclosure Policy:

    CMSC and NPA adhere to ANCC and ACCME Essential Areas, Standards and Policies regarding industry support of continuing medical education. Disclosure of the planning committee, content reviewers, and faculty commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussions of any off-label, experimental or investigational uses of drugs or devices in their presentations.

    Resolutions of Conflicts of Interest:
    In accordance with the ANCC and the ACCME Standards for Commercial Support of CME/CMSC and NPA will implement mechanisms, prior to the planning and implementation of this CME/CNE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CNE activity.



    Kottil Rammohan, MD

    University of Miami Miller School of Medicine

    Miami, Florida

    Michael Kaufman, MD
    Carolinas MS Center
    Charlotte, NC

    Joseph R. Berger, MD
    University of Kentucky
    Lexington, KY

    Edward Fox, MD, PhD
    Central Texas Neurology
    Austin, TX

    Stephen D. Miller, PhD
    Northwestern University
    Chicago, IL

    John Rose, MD
    University of Utah
    Salt Lake City, UT

    Jerry S. Wolinsky, MD
    The University of Texas Health Science Center
    Houston, TX


    Registration Fee:Complimentary! However, you will be asked to provide credit card information in order to guarantee your reservation. Credit cards will be charged a one-time $25 fee ONLY if you do not attend and do not cancel your registration by October 4, 2013.
    Registration Deadline:October 4, 2013
    How to register:

    Registration will not be accepted via telephone.

    Pre-registration is strongly encouraged. We cannot guarantee that we can accommodate on-site registrations.

    QuestionsPlease email or call (201) 487-1050


    « Go to Upcoming Event List
    Sign In

    Forgot your password?

    Haven't registered yet?

    Latest News
    Upcoming Events

    6/1/2016 » 6/4/2016
    2016 Consortium of Multiple Sclerosis Centers Annual Meeting

    6/23/2016 » 6/24/2016
    International MS Cognition Society Annual Meeting

    3 University Plaza Drive, Suite 116
    Hackensack, NJ 07601
    Tel: 201-487-1050 | Fax: 862-772-7275
    Privacy Policy | Disclaimer